Physician profile
Adam Kelman
NPI 1912065442
$5,269.33
in general payments reported to CMS, 2019-2025
26 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $466 · 2021: $523 · 2022: $579 · 2023: $507 · 2024: $567 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.34 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,270.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $969.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Senseonics, Incorporated | $381.00 | 2019-2020 | |
| Valeritas, INC. | $306.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $288.05 | 2019-2022 | |
| Corcept Therapeutics | $283.84 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $279.09 | 2019-2025 | |
| Amgen INC. | $274.85 | 2019-2025 | Evenity, Prolia |
| Sequel Med Tech, LLC | $158.71 | 2025 | Twiist |
| Medtronic, INC. | $144.27 | 2021-2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $124.99 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $124.75 | 2025 | Smoflipid |
| Insulet Corporation | $123.01 | 2022-2025 | Omnipod |
| Abbott Laboratories | $101.08 | 2021-2025 | Freestyle Libre 3 |
| Cequr Corporation | $98.44 | 2021-2024 | Cequr Simplicity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $93.23 | 2019-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $68.14 | 2021-2025 | Gvoke Hypopen |
| Ascensia Diabetes Care US INC. | $45.41 | 2025 | |
| Janssen Pharmaceuticals, INC | $26.28 | 2021 | |
| Radius Health, INC. | $22.67 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2025 | Jardiance |
| Tandem Diabetes Care, INC. | $17.09 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $13.53 | 2020 | |
| Shire North American Group INC | $13.21 | 2019 | |
| Beta Bionics, INC. | $12.05 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.